[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Driver et al., 2017 - Google Patents

Interferon-γ limits diabetogenic CD8+ T-cell effector responses in type 1 diabetes

Driver et al., 2017

View HTML
Document ID
2376900405136056355
Author
Driver J
Racine J
Ye C
Lamont D
Newby B
Leeth C
Chapman H
Brusko T
Chen Y
Mathews C
Serreze D
Publication year
Publication venue
Diabetes

External Links

Snippet

Type 1 diabetes development in the NOD mouse model is widely reported to be dependent on high-level production by autoreactive CD4+ and CD8+ T cells of interferon-γ (IFN-γ), generally considered a proinflammatory cytokine. However, IFN-γ can also participate in …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells

Similar Documents

Publication Publication Date Title
Driver et al. Interferon-γ limits diabetogenic CD8+ T-cell effector responses in type 1 diabetes
Lucca et al. Modulation of regulatory T cell function and stability by co-inhibitory receptors
Cadilha et al. Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors
Tu et al. T cell receptor-regulated TGF-β type I receptor expression determines T cell quiescence and activation
DiLillo et al. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer
Shevach Mechanisms of foxp3+ T regulatory cell-mediated suppression
Koch et al. T-bet+ Treg cells undergo abortive Th1 cell differentiation due to impaired expression of IL-12 receptor β2
Domeier et al. IFN-γ receptor and STAT1 signaling in B cells are central to spontaneous germinal center formation and autoimmunity
Fallet et al. Interferon-driven deletion of antiviral B cells at the onset of chronic infection
Le Mercier et al. Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators
Klose et al. The transcription factor T-bet is induced by IL-15 and thymic agonist selection and controls CD8αα+ intraepithelial lymphocyte development
Lu et al. Regulation of activated CD4+ T cells by NK cells via the Qa-1–NKG2A inhibitory pathway
US10577586B2 (en) Compositions and methods for modulating an immune response
Gabryšová et al. Integrated T‐cell receptor and costimulatory signals determine TGF‐β‐dependent differentiation and maintenance of Foxp3+ regulatory T cells
Wang et al. The four types of Tregs in malignant lymphomas
Lourenço et al. Natural regulatory T cells in autoimmunity
Gao et al. Regulation of antigen‐expressing dendritic cells by double negative regulatory T cells
Yang et al. Pancreatic islet-specific engineered Tregs exhibit robust antigen-specific and bystander immune suppression in type 1 diabetes models
Watanabe et al. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies
Portillo et al. Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors
Garidou et al. Therapeutic blockade of transforming growth factor beta fails to promote clearance of a persistent viral infection
Nabekura et al. Antigen-specific expansion and differentiation of natural killer cells by alloantigen stimulation
Mutnal et al. Infiltrating regulatory B cells control neuroinflammation following viral brain infection
Delgobo et al. Myocardial milieu favors local differentiation of regulatory T cells
Papadakis et al. Krüppel-like factor KLF10 regulates transforming growth factor receptor II expression and TGF-β signaling in CD8+ T lymphocytes